In a report released today, Chad Messer from Needham reiterated a Buy rating on Athenex (ATNX), with a price target of $30.00. The company’s shares closed last Monday at $15.18.
According to TipRanks.com, Messer is a 4-star analyst with an average return of 4.5% and a 40.8% success rate. Messer covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Aeglea Biotherapeutics, and Aerpio Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Athenex with a $30.00 average price target, which is a 143.9% upside from current levels. In a report released today, RBC Capital also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $21.11 and a one-year low of $8.82. Currently, Athenex has an average volume of 779.8K.
Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ATNX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer.It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform.
